Compares cilta-cel outcomes to bispecific antibodies in relapsed/refractory multiple myeloma, suggesting potential benefits for patients.
Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) have emerged as transformative options for patients with relapsed or refractory multiple myeloma (RRMM). Both modali...
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: